Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.18 -6.49%

-$0.30 today

Market cap
$108.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.28M

Average 0.21M

NERV Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Minerva Neurosciences, Inc.NASDAQ: NERV

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows 762040.4% year over year

Q2 FY2026 stock-based compensation of $2.27B rose 762040.4% year over year. Sequentially, it fell 73.9% from the prior quarter. Over 3 fiscal years it compounded at +586.2% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.27B-73.9% QoQ
Last fiscal yearDec 2025
$1.33B+100039.3% YoY
LTMJun 2026
$10.98B— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+762040.4%——
1 year+100039.3%——
3-year CAGR+586.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
1.33B USD
Year-over-year change
+100039.3%
4-year CAGR
+299.3%

Stock-Based Compensation vs competitors

How NERV compares with its peers on the latest reported figures

  • NERV's LTM Jun 2026 stock-based compensation of $10.98B is the largest of the 4 companies compared; the peer median is $1.78M.
  • Over three fiscal years its annual growth of +586.2% compares with a peer median of -13.0%.
NERV Competitors Peer median
Stock-Based Compensation for NERV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$10.98B —+586.2%—
RLYBRallybio CorporationLTM Mar 2026$4.05M -48.0%-17.6%471.8%
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$1.78M -13.7%-13.0%—
NRXSNeurAxis, Inc.LTM Mar 2026$819.93K -33.5%+179.6%19.2%
Peer median (excluding NERV) $1.78M-33.5%-13.0%245.5%

Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.91M)(32.11M)(30.01M)1.44M(293.42M)
Depreciation & Amortization101.79K8.51K30.98K22.47K5.44M
Deferred Income Tax(1.8M)0000
Stock-Based Compensation5.22M4.11M1.97M1.33M1.33B
Change in Working Capital259.34K(4.06M)4.94M(320.6K)(632.35K)
Accounts Receivables00000
Inventory00000
Accounts Payables857.6K(883.55K)835.65K(197.48K)(1.06M)
Other Working Capital(598.27K)(3.18M)4.1M(123.13K)426.67K
Other Non-Cash Items21.53M7.41M8.28M(22.02M)(14.55B)
Operating Cash Flow(24.6M)(24.65M)(14.78M)(19.55M)(13.51B)
Capital Expenditures0(16.33K)000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(16.33K)000
Debt Repayment00000
Common Stock Issued0020M074.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities60M(5)(396.29K)074.38B
Financing Cash Flow60M(5)19.6M074.45B
Effect of Forex Changes00000
Net Change in Cash35.4M(24.66M)4.82M(19.55M)60.94B
Free Cash Flow(24.6M)(24.66M)(14.78M)(19.55M)(13.51B)

Minerva Neurosciences, Inc.

NASDAQ:NERV

Intrinsic Alpha fair value

Locked

Current Price

$2.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.